News
Heidelberg Pharma invites individual and institutional investors, as well as advisors and analysts, to attend online at ...
Innovent Biologics presents data from phase 1 PoC study of IBI363 to treat advanced NSCLC at 2025 ASCO: San Francisco Friday, June 6, 2025, 18:00 Hrs [IST] Innovent Biologics, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback